The Health Insurance Fund focuses on access to insure fully subsidized treatment for rare diseases. In the end of 2011, they announced an 8% increase in its budget for 2012.
Biotechnology companies and the pharmaceutical industry are investing in innovative technologies for orphan drugs in order to help the easy and early access to treatment, and every initiative is welcome.
Click here to see the full information.
How can we continue to improve orphan drug access for rare disease patients? There is no easy answer, but industry stakeholders and regulators will come together at Terrapinn’s World Orphan Drug Congress USA 2012 this April.
North America’s leading orphan drug conference brings together leading pharma and biotech executives to strategize about the opportunities and challenges in commercializing treatments for rare and ultra-rare diseases.